Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Pharmaceutical Design
  4. Volume 31, Issue 6
  5. Article
Volume 31, Issue 6
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Ulcerative Colitis (UC) known as a sub-category of Inflammatory Bowel Diseases (IBD) is a long-term condition that causes inflammation, irritation, and ulcers in the colon and rectum. Though the precise pathogenesis of UC is not fully understood yet, impaired immune responses and imbalanced intestinal microbiome composition have been regarded as two main key players in colitis pathobiology. As conventional treatments are challenged with limitations and side effects, finding a new therapeutic approach has gained increasing attention. Probiotic bacteria with multifunctional health-promoting properties have been considered novel therapeutic options. There is strong evidence indicating that probiotics exert their therapeutic effects mostly by regulating immune system responses and restoring gut microbiome homeostasis. These results validate the rationale behind the clinical application of probiotics in UC management whether prescribed alone or in combination with conventional therapy. This article explores the pathogenesis of UC, concentrating on the influence of immune dysregulation and intestinal microbiome imbalances. Also, it reviews recent , and clinical studies that have demonstrated the efficacy of species in decreasing UC symptoms by modifying immune responses, restoring gut microbiota balance, and promoting intestinal barrier function.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128322653240925115114
2024-10-08
2025-01-18

  • From This Site

    /content/journals/cpd/10.2174/0113816128322653240925115114
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. GajendranM. LoganathanP. JimenezG. CatinellaA.P. NgN. UmapathyC. ZiadeN. HashashJ.G. A comprehensive review and update on ulcerative colitis.Dis. Mon.2019651210085110.1016/j.disamonth.2019.02.00430837080
     [Google Scholar]
  2. MagroF. LangnerC. DriessenA. EnsariA. GeboesK. MantzarisG.J. VillanacciV. BecheanuG. NunesP.B. CathomasG. FriesW. Jouret-MourinA. MescoliC. de PetrisG. RubioC.A. ShepherdN.A. ViethM. EliakimR. European consensus on the histopathology of inflammatory bowel disease.J. Crohn’s Colitis201371082785110.1016/j.crohns.2013.06.00123870728
     [Google Scholar]
  3. KaurL GordonM BainesPA Probiotics for induction of remission in ulcerative colitis.Cochrane Database Syst. Rev.202033CD00557310.1002/14651858.CD005573.pub3
     [Google Scholar]
  4. TripathiK. FeuersteinJ.D. New developments in ulcerative colitis: Latest evidence on management, treatment, and maintenance.Drugs Context2019811110.7573/dic.21257231065290
     [Google Scholar]
  5. SharmaN. SharmaA. BhatnagarA. NishadD. KarwasraR. KhannaK. SharmaD. KumarN. JainG.K. Novel gum acacia based macroparticles for colon delivery of Mesalazine: Development and gammascintigraphy study.J. Drug Deliv. Sci. Technol.20195410122410.1016/j.jddst.2019.101224
     [Google Scholar]
  6. HirankarnN. KimkongI. KummeeP. TangkijvanichP. PoovorawanY. Interleukin-1β gene polymorphism associated with hepatocellular carcinoma in hepatitis B virus infection.World J. Gastroenterol.200612577677910.3748/wjg.v12.i5.77616521194
     [Google Scholar]
  7. NiJ. WuG.D. AlbenbergL. TomovV.T. Gut microbiota and IBD: Causation or correlation?Nat. Rev. Gastroenterol. Hepatol.2017141057358410.1038/nrgastro.2017.8828743984
     [Google Scholar]
  8. SchwartzM. CohenR. Optimizing conventional therapy for inflammatory bowel disease.Curr. Gastroenterol. Rep.200810658559010.1007/s11894‑008‑0106‑819006615
     [Google Scholar]
  9. WilsonD.C. ThomasA.G. CroftN.M. NewbyE. AkobengA.K. SawczenkoA. FellJ.M.E. MurphyM.S. BeattieR.M. SandhuB.K. MittonS.G. CassonD. ElawadM. HeuschkelR. JenkinsH. JohnsonT. MacdonaldS. MurchS.H. Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease.J. Pediatr. Gastroenterol. Nutr.201050S1S14S3410.1097/MPG.0b013e3181c92caa20081542
     [Google Scholar]
  10. UngaroR. MehandruS. AllenP.B. Peyrin-BirouletL. ColombelJ.F. Ulcerative colitis.Lancet2017389100801756177010.1016/S0140‑6736(16)32126‑227914657
     [Google Scholar]
  11. ColombelJ.F. SandsB.E. RutgeertsP. SandbornW. DaneseS. D’HaensG. PanaccioneR. LoftusE.V.Jr SankohS. FoxI. ParikhA. MilchC. AbhyankarB. FeaganB.G. The safety of vedolizumab for ulcerative colitis and Crohn’s disease.Gut201766583985110.1136/gutjnl‑2015‑31107926893500
     [Google Scholar]
  12. SandbornW.J. SuC. SandsB.E. D’HaensG.R. VermeireS. SchreiberS. DaneseS. FeaganB.G. ReinischW. NiezychowskiW. FriedmanG. LawendyN. YuD. WoodworthD. MukherjeeA. ZhangH. HealeyP. PanésJ. Tofacitinib as induction and maintenance therapy for ulcerative colitis.N. Engl. J. Med.2017376181723173610.1056/NEJMoa160691028467869
     [Google Scholar]
  13. NishidaA. InoueR. InatomiO. BambaS. NaitoY. AndohA. Gut microbiota in the pathogenesis of inflammatory bowel disease.Clin. J. Gastroenterol.201811111010.1007/s12328‑017‑0813‑529285689
     [Google Scholar]
  14. MatthesH. KrummenerlT. GienschM. WolffC. SchulzeJ. Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN).BMC Complement. Altern. Med.20101011310.1186/1472‑6882‑10‑1320398311
     [Google Scholar]
  15. SharmaN. AroraA. KakkarD. Natural polysaccharides for ulcerative colitis: A general overview.Asian Pac. J. Trop. Biomed.202313518519410.4103/2221‑1691.377405
     [Google Scholar]
  16. ZhuL.R. LiS.S. ZhengW.Q. NiW.J. CaiM. LiuH.P. Targeted modulation of gut microbiota by traditional Chinese medicine and natural products for liver disease therapy.Front. Immunol.202314108607810.3389/fimmu.2023.108607836817459
     [Google Scholar]
  17. AlagiakrishnanK. MorgadinhoJ. HalversonT. Approach to the diagnosis and management of dysbiosis.Front. Nutr.202411133090310.3389/fnut.2024.133090338706561
     [Google Scholar]
  18. AlshehriD. SaadahO. MosliM. EdrisS. AlhindiR. BahieldinA. Dysbiosis of gut microbiota in inflammatory bowel disease: Current therapies and potential for microbiota-modulating therapeutic approaches.Bosn. J. Basic Med. Sci.202121327028333052081
     [Google Scholar]
  19. De FilippisA. UllahH. BaldiA. DacremaM. EspositoC. GarzarellaE.U. SantarcangeloC. TantipongpiradetA. DagliaM. Gastrointestinal disorders and metabolic syndrome: Dysbiosis as a key link and common bioactive dietary components useful for their treatment.Int. J. Mol. Sci.20202114492910.3390/ijms2114492932668581
     [Google Scholar]
  20. Zakerska-BanaszakO. TomczakH. GabryelM. BaturoA. WolkoL. MichalakM. MalinskaN. Mankowska-WierzbickaD. EderP. DobrowolskaA. SlomskiR. Skrzypczak-ZielinskaM. Dysbiosis of gut microbiota in polish patients with ulcerative colitis: A pilot study.Sci. Rep.2021111216610.1038/s41598‑021‑81628‑333495479
     [Google Scholar]
  21. TalapkoJ. VčevA. MeštrovićT. PustijanacE. JukićM. ŠkrlecI. Homeostasis and dysbiosis of the intestinal microbiota: Comparing hallmarks of a healthy state with changes in inflammatory bowel disease.Microorganisms20221012240510.3390/microorganisms1012240536557658
     [Google Scholar]
  22. DhillonP. SinghK. Therapeutic applications of probiotics in ulcerative colitis: An updated review.PharmaNutrition20201310019410.1016/j.phanu.2020.100194
     [Google Scholar]
  23. ChibbarR. DielemanL.A. Probiotics in the management of ulcerative colitis.J. Clin. Gastroenterol.201549S50S5510.1097/MCG.000000000000036826447965
     [Google Scholar]
  24. van der WaalM.B. FlachJ. BrowneP.D. Besseling-van der VaartI. ClaassenE. van de BurgwalL.H.M. Probiotics for improving quality of life in ulcerative colitis: Exploring the patient perspective.PharmaNutrition2019710013910.1016/j.phanu.2018.100139
     [Google Scholar]
  25. MurrayA NguyenTM ParkerCE FeaganBG MacDonaldJK Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev.202088CD00054310.1002/14651858.CD000543.pub5
     [Google Scholar]
  26. LouisE. ParidaensK. Al AwadhiS. BegunJ. CheonJ.H. DignassA.U. MagroF. MárquezJ.R. MoschenA.R. NarulaN. RydzewskaG. FreddiM.J. TravisS.P.L. Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis.BMJ Open Gastroenterol.202291e00085310.1136/bmjgast‑2021‑00085335165124
     [Google Scholar]
  27. DorringtonA.M. SelingerC.P. ParkesG.C. SmithM. PollokR.C. RaineT. The historical role and contemporary use of corticosteroids in inflammatory bowel disease.J. Crohn’s Colitis20201491316132910.1093/ecco‑jcc/jjaa05332170314
     [Google Scholar]
  28. CalméjaneL. LaharieD. KirchgesnerJ. UzzanM. Review article: Updated management of acute severe ulcerative colitis: From steroids to novel medical strategies.United Eur. Gastroenterol. J.202311872273210.1002/ueg2.1244237475143
     [Google Scholar]
  29. SinghS AllegrettiJR SiddiqueSM TerdimanJP AGA technical review on the management of moderate to severe ulcerative colitis.Gastroenterology2020158514651496.e1710.1053/j.gastro.2020.01.007
     [Google Scholar]
  30. ChhibbaT. MaC. Is there room for immunomodulators in ulcerative colitis?Expert Opin. Biol. Ther.202020437939010.1080/14712598.2020.170889631874578
     [Google Scholar]
  31. ZhouH.Y. GuoB. LufumpaE. LiX.M. ChenL.H. MengX. LiB.Z. Comparative of the effectiveness and safety of biological agents, tofacitinib, and fecal microbiota transplantation in ulcerative colitis: Systematic review and network meta-analysis.Immunol. Invest.202150432333710.1080/08820139.2020.171465032009472
     [Google Scholar]
  32. SinghS FacciorussoA DulaiPS JairathV SandbornWJ Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: A systematic review and meta-analysis.Clin. Gastroenterol. Hepatol.20201816981.e310.1016/j.cgh.2019.02.044
     [Google Scholar]
  33. LeB. YangS.H. Efficacy of Lactobacillus plantarum in prevention of inflammatory bowel disease.Toxicol. Rep.2018531431710.1016/j.toxrep.2018.02.00729854599
     [Google Scholar]
  34. SunM. LiuY. SongY. GaoY. ZhaoF. LuoY. QianF. MuG. TuoY. The ameliorative effect of Lactobacillus plantarum-12 on DSS-induced murine colitis.Food Funct.20201165205522210.1039/D0FO00007H32458908
     [Google Scholar]
  35. TanakaA. KanmuraS. MorinagaY. KawabataK. ArimaS. SasakiF. NasuY. TanoueS. HashimotoS. TakeshitaM. TakedaS. IdoA. Oral administration of Lactobacillus plantarum 06CC2 prevents experimental colitis in mice via an anti-inflammatory response.Mol. Med. Rep.20202131181119110.3892/mmr.2020.1092531922249
     [Google Scholar]
  36. PanY. NingY. HuJ. WangZ. ChenX. ZhaoX. The preventive effect of Lactobacillus plantarum ZS62 on DSS-induced IBD by regulating oxidative stress and the immune response.Oxid. Med. Cell. Longev.202120211941679410.1155/2021/941679434745426
     [Google Scholar]
  37. JinJ. WuS. XieY. LiuH. GaoX. ZhangH. Live and heat-killed cells of Lactobacillus plantarum Zhang-LL ease symptoms of chronic ulcerative colitis induced by dextran sulfate sodium in rats.J. Funct. Foods20207110399410.1016/j.jff.2020.103994
     [Google Scholar]
  38. ZhangC. ZhaoY. JiangJ. YuL. TianF. ZhaoJ. ZhangH. ChenW. ZhaiQ. Identification of the key characteristics of Bifidobacterium longum strains for the alleviation of ulcerative colitis.Food Funct.20211283476349210.1039/D1FO00017A33900330
     [Google Scholar]
  39. YuP. KeC. GuoJ. ZhangX. LiB. Lactobacillus plantarum L15 alleviates colitis by inhibiting LPS-mediated NF-κB activation and ameliorates DSS-induced gut microbiota dysbiosis.Front. Immunol.20201157517310.3389/fimmu.2020.57517333123156
     [Google Scholar]
  40. WangH. ZhouC. HuangJ. KuaiX. ShaoX. The potential therapeutic role of Lactobacillus reuteri for treatment of inflammatory bowel disease.Am. J. Transl. Res.20201251569158332509162
     [Google Scholar]
  41. KrishnaM. EngevikM. QuelizaK. BrittoS. ShahR. RuanW. WangH. VersalovicJ. KellermayerR. Maternal Lactobacillus reuteri supplementation shifts the intestinal microbiome in mice and provides protection from experimental colitis in female offspring.FASEB Bioadv.20224210912010.1096/fba.2021‑0007835141475
     [Google Scholar]
  42. HeL. ZhouX. LiuY. ZhouL. LiF. Fecal miR-142a-3p from dextran sulfate sodium-challenge recovered mice prevents colitis by promoting the growth of Lactobacillus reuteri.Mol. Ther.202230138839910.1016/j.ymthe.2021.08.02534450255
     [Google Scholar]
  43. WangT. ZhengN. LuoQ. JiangL. HeB. YuanX. ShenL. Probiotics Lactobacillus reuteri abrogates immune checkpoint blockade-associated colitis by inhibiting group 3 innate lymphoid cells.Front. Immunol.201910123510.3389/fimmu.2019.0123531214189
     [Google Scholar]
  44. SunM. ZhangF. YinX. ChengB. ZhaoC. WangY. ZhangZ. HaoH. ZhangT. YeH. Lactobacillus reuteri F-9-35 prevents DSS-induced colitis by inhibiting proinflammatory gene expression and restoring the gut microbiota in mice.J. Food Sci.201883102645265210.1111/1750‑3841.1432630216448
     [Google Scholar]
  45. WangG. HuangS. CaiS. YuH. WangY. ZengX. QiaoS. Lactobacillus reuteri ameliorates intestinal inflammation and modulates gut microbiota and metabolic disorders in dextran sulfate sodium-induced colitis in mice.Nutrients2020128229810.3390/nu1208229832751784
     [Google Scholar]
  46. ChenL ZouY PengJ LuF YinY LiF YangJ Lactobacillus acidophilus suppresses colitis-associated activation of the IL-23/Th17 axis.J. Immunol. Res.2015201590951410.1155/2015/909514
     [Google Scholar]
  47. AghamohammadS. SepehrA. MiriS.T. NajafiS. PourshafieM.R. RohaniM. Anti-inflammatory and immunomodulatory effects of Lactobacillus spp. as a preservative and therapeutic agent for IBD control.Immun. Inflamm. Dis.2022106e63510.1002/iid3.63535634951
     [Google Scholar]
  48. HuT. WangH. XiangC. MuJ. ZhaoX. Preventive effect of Lactobacillus acidophilus XY27 on DSS-induced ulcerative colitis in mice.Drug Des. Devel. Ther.2020145645565710.2147/DDDT.S28442233376308
     [Google Scholar]
  49. WuZ. PanD. JiangM. SangL. ChangB. Selenium-enriched Lactobacillus acidophilus ameliorates dextran sulfate sodium-induced chronic colitis in mice by regulating inflammatory cytokines and intestinal microbiota.Front. Med. (Lausanne)2021871681610.3389/fmed.2021.71681634532332
     [Google Scholar]
  50. ShinM.Y. YongC.C. OhS. Regulatory effect of Lactobacillus brevis Bmb6 on gut barrier functions in experimental colitis.Foods20209786410.3390/foods907086432630643
     [Google Scholar]
  51. DingS. MaY. LiuG. YanW. JiangH. FangJ. Lactobacillus brevis alleviates DSS-induced colitis by reprograming intestinal microbiota and influencing serum metabolome in murine model.Front. Physiol.201910115210.3389/fphys.2019.0115231620010
     [Google Scholar]
  52. WongW.Y. ChanB.D. ShamT.T. LeeM.M.L. ChanC.O. ChauC.T. MokD.K-W. KwanY-W. TaiW.C-S. Lactobacillus casei strain Shirota ameliorates dextran sulfate sodium-induced colitis in mice by increasing taurine-conjugated bile acids and inhibiting NF-κB signaling via stabilization of IκBα.Front. Nutr.2022981683610.3389/fnut.2022.816836
     [Google Scholar]
  53. SuL. MaF. AnZ. JiX. ZhangP. YueQ. ZhaoC. SunX. LiK. LiB. LiuX. ZhaoL. The metabolites of Lactobacillus fermentum F-B9-1 relieved dextran sulfate sodium-induced experimental ulcerative colitis in mice.Front. Microbiol.20221386592510.3389/fmicb.2022.86592535572623
     [Google Scholar]
  54. LiuY. ZhengS. CuiJ. GuoT. ZhangJ. LiB. Alleviative effects of exopolysaccharide produced by Lactobacillus helveticus KLDS1.8701 on dextran sulfate sodium-induced colitis in mice.Microorganisms2021910208610.3390/microorganisms910208634683406
     [Google Scholar]
  55. HuangJ. YangZ. LiY. ChaiX. LiangY. LinB. YeZ. ZhangS. CheZ. ZhangH. ZhangX. ZhangZ. ChenT. YangW. ZengJ. Lactobacillus paracasei R3 protects against dextran sulfate sodium (DSS)-induced colitis in mice via regulating Th17/Treg cell balance.J. Transl. Med.202119135610.1186/s12967‑021‑02943‑x34407839
     [Google Scholar]
  56. PangB. JinH. LiaoN. LiJ. JiangC. ShaoD. ShiJ. Lactobacillus rhamnosus from human breast milk ameliorates ulcerative colitis in mice via gut microbiota modulation.Food Funct.202112115171518610.1039/D0FO03479G33977948
     [Google Scholar]
  57. LeeJ. ParkS.B. KimH.W. LeeH.S. JeeS.R. LeeJ.H. KimT.O. Clinical efficacy of probiotic therapy on bowel-related symptoms in patients with ulcerative colitis during endoscopic remission: An observational study.Gastroenterol. Res. Pract.2022202211510.1155/2022/987223035082846
     [Google Scholar]
  58. BjarnasonI. SissionG. HayeeB.H. A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn’s disease.Inflammopharmacology201927346547310.1007/s10787‑019‑00595‑431054010
     [Google Scholar]
  59. Kamarli AltunH. Akal YildizE. AkinM. Effects of synbiotic therapy in mild-to-moderately active ulcerative colitis: A randomized placebo-controlled study.Turk. J. Gastroenterol.201930431332010.5152/tjg.2019.1835630666969
     [Google Scholar]
  60. ChenP. XuH. TangH. ZhaoF. YangC. KwokL.Y. CongC. WuY. ZhangW. ZhouX. ZhangH. Modulation of gut mucosal microbiota as a mechanism of probiotics-based adjunctive therapy for ulcerative colitis.Microb. Biotechnol.20201362032204310.1111/1751‑7915.1366132969200
     [Google Scholar]
  61. Pilarczyk-ZurekM WcisłoM MachT Influence of Lactobacillus and Bifidobacterium combination on the gut microbiota, clinical course, and local gut inflammation in patients with ulcerative colitis: A preliminary, single-center, open-label study. J. Prob. Health20175116310.4172/2329‑8901.1000163
     [Google Scholar]
  62. PalumboV.D. RomeoM. GammazzaA.M. CariniF. DamianiP. DamianoG. BuscemiS. Lo MonteA.I. Gerges-GeageaA. JurjusA. TomaselloG. The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study.Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub.2016160337237710.5507/bp.2016.04427623957
     [Google Scholar]
  63. OlivaS. Di NardoG. FerrariF. MallardoS. RossiP. PatriziG. CucchiaraS. StronatiL. Randomised clinical trial: The effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis.Aliment. Pharmacol. Ther.201235332733410.1111/j.1365‑2036.2011.04939.x22150569
     [Google Scholar]
  64. D’IncàR. BarolloM. ScarpaM. GrilloA.R. BrunP. VettoratoM.G. CastagliuoloI. SturnioloG.C. Rectal administration of Lactobacillus casei DG modifies flora composition and Toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis.Dig. Dis. Sci.20115641178118710.1007/s10620‑010‑1384‑120737210
     [Google Scholar]
  65. HegazyS.K. El-BedewyM.M. Effect of probiotics on pro-inflammatory cytokines and NF-κB activation in ulcerative colitis.World J. Gastroenterol.201016334145415110.3748/wjg.v16.i33.414520806430
     [Google Scholar]
  66. ZoccoM.A. Dal VermeL.Z. CremoniniF. PiscagliaA.C. NistaE.C. CandelliM. NoviM. RiganteD. CazzatoI.A. OjettiV. ArmuzziA. GasbarriniG. GasbarriniA. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis.Aliment. Pharmacol. Ther.200623111567157410.1111/j.1365‑2036.2006.02927.x16696804
     [Google Scholar]
/content/journals/cpd/10.2174/0113816128322653240925115114
Loading
Evaluating the Therapeutic Efficacy of Lactobacillus Strains in the Management of Ulcerative Colitis: An Overview of Recent Advances
Curr. Pharm. Des. 31, 413 (2025); https://doi.org/10.2174/0113816128322653240925115114
/content/journals/cpd/10.2174/0113816128322653240925115114
/content/journals/cpd/10.2174/0113816128322653240925115114
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): fibrosis; immune responses; inflammation; intestinal microbiome; probiotics; Ulcerative colitis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test